198 related articles for article (PubMed ID: 20566700)
1. Major molecular response in CML patients treated with tyrosine kinase inhibitors: the paradigm for monitoring targeted cancer therapy.
Press RD
Oncologist; 2010; 15(7):744-9. PubMed ID: 20566700
[TBL] [Abstract][Full Text] [Related]
2. 3. Imatinib therapy in chronic myelogenous leukemia.
Jinnai I
Intern Med; 2007; 46(2):95-7. PubMed ID: 17220607
[No Abstract] [Full Text] [Related]
3. First-line therapy for CML: nilotinib comes of age.
Davies J
Lancet Oncol; 2011 Sep; 12(9):826-7. PubMed ID: 21856227
[No Abstract] [Full Text] [Related]
4. 10 years of progress in chronic myelogenous leukemia.
Jabbour E; Mathisen MS; O'Brien S
J Natl Compr Canc Netw; 2012 Sep; 10(9):1049-53. PubMed ID: 22956803
[No Abstract] [Full Text] [Related]
5. Drug developers unveil strategies aimed at imatinib-resistant CML.
Goozner M
J Natl Cancer Inst; 2010 May; 102(9):593-5. PubMed ID: 20421566
[No Abstract] [Full Text] [Related]
6. [Tyrosine kinase inhibitors in the therapy of chronic myeloid leukaemia].
Grzybowska-Izydorczyk O; Góra-Tybor J; Robak T
Postepy Hig Med Dosw (Online); 2006; 60():490-7. PubMed ID: 17013368
[TBL] [Abstract][Full Text] [Related]
7. Chronic myeloid leukemia. Sceptical scientists.
Druker BJ
Lancet; 2001 Dec; 358 Suppl():S11. PubMed ID: 11784560
[No Abstract] [Full Text] [Related]
8. BCR-ABL tyrosine kinase inhibitors for chronic myelogenous leukemia.
Schiffer CA
N Engl J Med; 2007 Jul; 357(3):258-65. PubMed ID: 17634461
[No Abstract] [Full Text] [Related]
9. Dasatinib for the treatment of Philadelphia chromosome-positive leukaemias.
Jabbour E; Cortes J; Kantarjian H
Expert Opin Investig Drugs; 2007 May; 16(5):679-87. PubMed ID: 17461740
[TBL] [Abstract][Full Text] [Related]
10. Monitoring minimal residual disease in BCR-ABL-positive chronic myeloid leukemia in the imatinib era.
Goldman J
Curr Opin Hematol; 2005 Jan; 12(1):33-9. PubMed ID: 15604889
[TBL] [Abstract][Full Text] [Related]
11. PD166326, a novel tyrosine kinase inhibitor, has greater antileukemic activity than imatinib mesylate in a murine model of chronic myeloid leukemia.
Wolff NC; Veach DR; Tong WP; Bornmann WG; Clarkson B; Ilaria RL
Blood; 2005 May; 105(10):3995-4003. PubMed ID: 15657179
[TBL] [Abstract][Full Text] [Related]
12. Therapy options in imatinib failures.
Ramirez P; DiPersio JF
Oncologist; 2008 Apr; 13(4):424-34. PubMed ID: 18448557
[TBL] [Abstract][Full Text] [Related]
13. Second generation tyrosine kinase inhibitors for the treatment of chronic myelogenous leukemia. [An interview with Hagop Katarjian by H&O].
Kantarjian H
Clin Adv Hematol Oncol; 2008 Nov; 6(11):797-9. PubMed ID: 19194361
[No Abstract] [Full Text] [Related]
14. Structural modeling of V299L and E459K Bcr-Abl mutation, and sequential therapy of tyrosine kinase inhibitors for the compound mutations.
Kim D; Kim DW; Cho BS; Goh HG; Kim SH; Kim WS; Lee J; Kweon IY; Park SH; Yoon JH; Kim ND; Chun H
Leuk Res; 2009 Sep; 33(9):1260-5. PubMed ID: 19201023
[TBL] [Abstract][Full Text] [Related]
15. STI571 (imatinib mesylate): the tale of a targeted therapy.
Thambi P; Sausville EA
Anticancer Drugs; 2002 Feb; 13(2):111-4. PubMed ID: 11901302
[TBL] [Abstract][Full Text] [Related]
16. Chronic myelogenous leukaemia--new therapeutic principles.
O'Dwyer ME; Druker BJ
J Intern Med; 2001 Jul; 250(1):3-9. PubMed ID: 11454136
[TBL] [Abstract][Full Text] [Related]
17. Status of bcr-abl tyrosine kinase inhibitors in chronic myelogenous leukemia.
O'Dwyer ME; Druker BJ
Curr Opin Oncol; 2000 Nov; 12(6):594-7. PubMed ID: 11085460
[TBL] [Abstract][Full Text] [Related]
18. Hematology: Nilotinib and dasatinib--new 'magic bullets' for CML?
Breccia M
Nat Rev Clin Oncol; 2010 Oct; 7(10):557-8. PubMed ID: 20877419
[No Abstract] [Full Text] [Related]
19. Disabling Abl-perspectives on Abl kinase regulation and cancer therapeutics.
Sawyers CL
Cancer Cell; 2002 Feb; 1(1):13-5. PubMed ID: 12086882
[TBL] [Abstract][Full Text] [Related]
20. As leukemia options grow, drugs jockey to be first-line therapies.
Dolgin E
Nat Med; 2013 Jan; 19(1):7. PubMed ID: 23295994
[No Abstract] [Full Text] [Related]
[Next] [New Search]